IntroductionBruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved pirtobrutinib for certain adults with relapsed or refractory chronic lymphocytic leukemia ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

When mantle cell lymphoma stops responding to treatment, the options narrow fast. This rare but aggressive form of ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...

Imugene has reported promising Phase 1b data for azer-cel, its allogeneic CD19 CAR T-cell therapy, in a CAR T-naïve cohort of patients with relapsed or refractory non-Hodgkin lymphoma and chronic ...

—The subtype of lymphoma and the timing of anticancer treatment was shown to directly affect the level of seroconversion in cancer patients administered COVID vaccination. Reviewed by Catherine E. Lai ...

The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...

A positive mental attitude (PMA) is crucial for coping with an incurable cancer diagnosis, aiding in resilience and treatment adherence. Fourteen years post-diagnosis, a 50th wedding anniversary was ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...